New Urine Test Distinguishes Bipolar Disorder and Depression
A failure to diagnose bipolar disorder in patients who experience a major depressive period may lead to incorrect treatment and inferior consequences. Clinical and medical methods that could differentiate bipolar from unipolar depression would simplify more suitable treatment choice. Research found that bipolar depression was linked with family history of bipolar disorder, a larger previous number of depressive periods. Fears were more common in victims with bipolar disorder, while sorrow; insomnia; cognitive, somatic, respirational, genitourinary complaints; and depressed behavior were more common in patients with unipolar depression. Bipolar depression and major depressive disorder display delicate variances in demonstration, which may help guide the initial diagnosis.
Although through clinical research, psychology made a progress differentiating those two disorders an easy and still consistent medical method of distinguishing bipolar disorder from major depressive disorder could save many lives, and change many more. Researchers at Chongqing Medical University, China, state that they have found such a method in a study grounded on biomarkers in urine.
The popular image of someone with bipolar disorder is characterized by noticeable celebrities such as Carrie Fisher aka “Princess Leia” – attacks of severe mania interrupted by depression and leading to drug abuse. Actually, it is not easy to identify; even Fisher said she was officially diagnosed after her mid-20s. Moreover, as a new paper in The Journal Proteome research records, “Multiple depressive episodes usually occur prior to the first manic episode in many bipolar patients.”
In such circumstances, the signs of bipolar disorder can be very hard to separate from those of major depressive disorder (MDD). As MDD is the more shared disorder, clinicians frequently haste to an MDD diagnosis; actually, many don’t even consider to explore the probability of bipolar disorder. Research have found that as many as 39% of victims identified with MDD have unrecognized bipolar disorder.
The paper states: “A large percentage of BD subjects are incorrectly treated with antidepressants in clinical practice.” The costs can be deadly. Selective seratonin reuptake inhibitors (SSRIs) such as Prozac and Celexa perhaps don’t benefit people with bipolar disorder. SSRIs are suspected to surge suicide risk among bipolar patients, a main worry as people with bipolar disorder have suicide rates around 20 times the population.
Although efforts have been made to alert doctors to the hazards of this sort of incorrect conclusions, as long as we remain to trust only on multiple subtle signs, the problem will endure.
The Chongquing Medical University researchers consider they have created a way out of this problem, having acknowledged biomarkers whose absorptions are diverse for people with bipolar or MDD.
The researchers state that some of these biomarkers have been explored before, but alone did not deliver an adequately reliable method for diagnosis. Though, senior researcher Dr. Peng Xie projected that multiple markers in mixture might succeed where each had failed.
For the research, psychiatrists recruited 71 people with bipolar disorder, 126 with MDD, and 126 with no disorder. Each group was separated into an exercise set and a test set. For the exercise set, the researchers were told the subject’s disorder ahead of time and used this to classify applicable markers, while in the other group it was a blinded trial to check the predictive capacity of these markers. The researchers tested the urine of those in the training set to identify 20 metabolites linked with either MDD or bipolar disorder.
A preliminary trial on the test set acknowledged 76% of those with MDD and 79% of those with bipolar disorder, which is less than what would be required clinically. Though, when the results were reanalyzed, six metabolites were identified. After standardizing these six metabolites to creatinine concentration in urine, the researchers established that they could accomplish 90% reliability in distinguishing between the two conditions. As a result, the research adds to work published last year signifying biomarkers could play a major role in depression identification.